Refining metformin prescribing in New Zealand.

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• Metformin is a primary treatment for type 2 diabetes.
• Concerns exist regarding metformin use in renal impairment due to metformin-associated lactic acidosis (MALA).
• Recent research questions the link between metformin and MALA.

Purpose of the Study:

• To review the context and implications of updated Medsafe guidelines on metformin prescribing in renal impairment.
• To address concerns about metformin-associated lactic acidosis (MALA) in patients with reduced glomerular filtration rate (GFR).

Main Methods:

• Review of recent studies on metformin-associated lactic acidosis (MALA).
• Analysis of Medsafe's updated datasheet recommendations for metformin use in renal impairment.
• Discussion of the clinical implications of revised prescribing guidelines.

Main Results:

• Recent studies challenge the direct causality of MALA solely due to metformin.
• Medsafe now permits lower metformin doses for patients with GFR down to 15ml/min.
• This change reflects a re-evaluation of metformin safety in specific renal impairment contexts.

Conclusions:

• Updated guidelines facilitate safer metformin use in type 2 diabetes patients with moderate to severe renal impairment.
• The evidence suggests MALA is less common than previously feared in metformin users with reduced GFR.
• Further research may clarify the precise risks and benefits of metformin in diverse renal function categories.